(Q36216956)

12 August 2017

1 reference

title

Structural and biochemical properties of fibroblast growth factor 23. (English)

1 reference

12 August 2017

Takeyoshi Yamashita

1

1 reference

12 August 2017

publication date

1 August 2005

1 reference

Therapeutic Apheresis and Dialysis

12 August 2017

published in

1 reference

12 August 2017

volume

9

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

313-318

1 reference

Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

Evolution of the Fgf and Fgfr gene families

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

Effect of hydrolysis-resistant FGF23-R179Q on dietary phosphate regulation of the renal type-II Na/Pi transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

The phosphatonin pathway: new insights in phosphate homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

FGF-23 in patients with end-stage renal disease on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

Acute and chronic regulation of thick ascending limb endothelial nitric oxide synthase by statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1744-9987.2005.00288.X

10.1111/J.1744-9987.2005.00288.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference